---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-021251"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-05T00:08:28.507105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Q4 2023 update: cash $8.5M, tecarfarin expanded to LVADs and APS

## Summary
- Q4 2023 operating expenses (excl. non-cash) totaled $1,160,000; cash used in ops $694,000.
- Cash and equivalents at Dec 31, 2023: $8.5 million.
- Expanded tecarfarin development to include LVAD and APS patients, addressable market >$2B/yr in US.
- Appointed Jeff Cole as COO, overseeing manufacturing, supply chain, IP, and partnering.
- Engaged The Sage Group to explore strategic partnerships, co-development, and licensing for tecarfarin.

## SEC filing metadata
- accession: 0001213900-24-021251
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/0001213900-24-021251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/ea0201508-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-021251
- JSON: https://secwatch.observer/filing/0001213900-24-021251.json
- Plain text: https://secwatch.observer/filing/0001213900-24-021251.txt

## Key facts
- Earnings Releases
  Cadrenal Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/0001213900-24-021251-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.